Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update-Reference-Cited by-同舟云学术

Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update

Published:2017-02-13 Issue:1 Volume:102 Page:37-44
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Hicks JK¹,Sangkuhl K²,Swen JJ³,Ellingrod VL⁴,Müller DJ⁵,Shimoda K⁶,Bishop JR⁷,Kharasch ED⁸,Skaar TC⁹,Gaedigk A¹⁰,Dunnenberger HM¹¹,Klein TE²,Caudle KE¹²,Stingl JC¹³

Affiliation:

1. DeBartolo Family Personalized Medicine Institute; Division of Population Science, H. Lee Moffitt Cancer Center and Research Institute; Tampa Florida USA

2. Department of Genetics; Stanford University; Stanford California USA

3. Department of Clinical Pharmacy and Toxicology; Leiden University Medical Center; Leiden The Netherlands

4. Department of Clinical, Social and Administrative Sciences; College of Pharmacy, and Department of Psychiatry, School of Medicine, University of Michigan; Ann Arbor Michigan USA

5. Campbell Family Mental Health Research Institute; Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto; Toronto Ontario Canada

6. Department of Psychiatry; Dokkyo Medical University; Japan

7. Department of Experimental and Clinical Pharmacology; College of Pharmacy, and Department of Psychiatry, College of Medicine, University of Minnesota; Minneapolis Minnesota USA

8. Division of Clinical and Translational Research, Department of Anesthesiology; Washington University in St; Louis, St Louis Missouri USA

9. Division of Clinical Pharmacology, Department of Medicine; Indiana University School of Medicine; Indianapolis Indiana USA

10. Division of Clinical Pharmacology; Toxicology & Therapeutic Innovation, Children's Mercy, Kansas City, Missouri and Department of Pediatrics, University of Missouri-Kansas City; Kansas City Missouri USA

11. Center for Molecular Medicine; NorthShore University HealthSystem; Evanston Illinois USA

12. Department of Pharmaceutical Sciences; St. Jude Children's Research Hospital; Memphis Tennessee USA

13. Division of Research; Federal Institute of Drugs and Medical Devices; Bonn Germany

Funder

National Institutes of Health

CPIC

PharmGKB

Agency for Healthcare Research and Quality

NIMH

New Investigator Salary Award from the Canadian Institutes of Health Research

New Investigator Fellowship Award from the Ontario Mental Health Foundation

Early Researcher Award by the Ministry of Research and Innovation of Ontario

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference37 articles.

1. PGx Gene-specific Information Tables for CYP2D6 https://www.pharmgkb.org/page/cyp2d6RefMaterials 2016

2. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype;Gaedigk;Clin. Pharmacol. Ther.,2008

3. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors;Hicks;Clin. Pharmacol. Ther.,2015

4. PGx Gene-specific Information Tables for CYP2C19 https://www.pharmgkb.org/page/cyp2c19RefMaterials 2016

5. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy;Scott;Clin. Pharmacol. Ther.,2011

Cited by 501 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug metabolizing enzymes pharmacogenetic variation-informed antidepressant therapy approach for common mental disorders: A systematic review and meta-analysis;Journal of Affective Disorders;2024-12

2. Cost-effectiveness of pharmacogenetic screening in the management of major depressive disorder in the Spanish Healthcare System;Journal of Affective Disorders;2024-11

3. Long-read sequencing of CYP2D6 may improve psychotropic prescribing and treatment outcomes: A systematic review and meta-analysis;Journal of Psychopharmacology;2024-09-11

4. Development of a Multifaceted Program for Pharmacogenetics Adoption at an Academic Medical Center: Practical Considerations and Lessons Learned;Clinical Pharmacology & Therapeutics;2024-08-21

5. Challenges and prospects in bridging precision medicine and artificial intelligence in genomic psychiatric treatment;World Journal of Psychiatry;2024-08-19